หน้าแรก
ค้นหา
Dr. Jason Luke on Sequencing Targeted and Immunotherapy Agents in BRAF+ Melanoma
No description available
แสดงข้อมูลเพิ่มเติม 1
Dr. Jason Luke on Sequencing Targeted and Immunotherapy Agents in BRAF+ Melanoma
Dr. Jason Luke Discusses Nivolumab and Pembrolizumab in Melanoma
Dr. Luke on Challenges With Immunotherapy in Melanoma
Dr. Jason Luke Talks About Advances in how Melanoma is Diagnosed
Dr. Luke on Immunotherapy Diagnostics in Melanoma
Dr. Jason Luke Describes Results from the Phase III COMBI-d Trial
Dr. Puzanov on Sequencing Targeted Therapy and Immunotherapy in Melanoma
Jason Luke, MD: Second-Line Therapy
Jason J. Luke, MD, FACP, on how data from ESMO 2019 may impact the treatment of melanoma
Dr. Jason Luke on Utilizing the Tumor Microenvironment as a Biomarker for Immunotherapy Response
Sequencing Agents for the Treatment of Patients With Melanoma
Dr. Luke on the Clinical Trial Landscape for Melanoma
Dr. Lewis on Sequencing Immunotherapy and Targeted Therapy in Melanoma
Dr. Jason Luke Discusses the Giants of Cancer Care Program
Questions About Sequencing in BRAF-Mutant Melanoma
Dr. Jason Luke on the Importance of Discussing Value-Based Care
Dr. Postow on Sequencing Strategies in Treating Patients With Melanoma
Sequencing Decisions and Multidisciplinary Care in Metastatic Melanoma
Adil Daud, MD: Optimal Sequencing for BRAF-Mutant Melanoma Patients
Dr. Sosman on Drug Sequencing in Melanoma
